Fubotv earnings beat by $0.10, revenue topped estimates
These transactions were conducted under a pre-established trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, which allows company insiders to set up a trading plan for selling stocks they own.
These transactions were conducted under a pre-established trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, which allows company insiders to set up a trading plan for selling stocks they own.
These transactions were conducted under a pre-established trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, which allows company insiders to set up a trading plan for selling stocks they own.
In other recent news, NewAmsterdam Pharma is making strides in its clinical trials and preparing for global regulatory submissions for its cholesterol-lowering drug candidate, obicetrapib. Positive results from three Phase 3 trials, BROADWAY, TANDEM, and BROOKLYN, have set the stage for these anticipated filings. The BROADWAY study showed a significant reduction in major adverse cardiovascular events with a safety profile comparable to placebo.
Analyst firms H.C. Wainwright, Scotiabank (TSX:BNS), and Leerink Partners have issued positive ratings and upgraded their price targets for NewAmsterdam, following these developments. The company has also announced the termination of its $150 million share sale plan and restated its financial statements for the years ending 2022 and 2021 due to identified errors in the calculation of net loss per ordinary share.
NewAmsterdam is also making preparations for the anticipated U.S. and European launches of obicetrapib, pending approval. The company is currently conducting the VINCENT Phase 2 trial and the REMBRANDT Phase 3 imaging trial, which will further evaluate obicetrapib’s effects on cardiovascular health indicators. These are among the recent developments shaping the trajectory of NewAmsterdam Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.